NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
23,553.24 -38.67 (-0.16%)
Karolinska Development AB (publ) (KDEV.ST)
| Previous close | 2.7400 |
| Open | 2.5160 |
| Bid | 2.7140 x 0 |
| Ask | 2.7180 x 0 |
| Day's range | 2.7080 - 2.8160 |
| 52-week range | 1.5400 - 11.2400 |
| Volume | |
| Avg. volume | 595,171 |
| Market cap | 477.145M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 1.73 |
| EPS (TTM) | 1.5700 |
| Earnings date | 27 Apr 2022 - 02 May 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.30 |
- Globe Newswire
Karolinska Development's portfolio company Umecrine Cognition submits a Clinical Trial Application to initiate a phase 2 clinical trial with golexanolone
STOCKHOLM, SWEDEN – May 19, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has submitted a clinical trial application (CTA) to the Hungarian regulatory body OGÝEI for approval to initiate a Phase 2 clinical trial of its drug candidate golexanolone in patients suffering from primary biliary cholangitis. The study is planned to be conducted at several European clinical trial centers. Umecrine Cognition's drug candidate golexan
- Globe Newswire
Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals
STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition
- Globe Newswire
Karolinska Development’s Annual General Meeting 2022
STOCKHOLM, SWEDEN – May 12, 2022. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 12, 2022. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the choice to exercise their voting rights at the AGM by attending in person, by postal voting or through a proxy. The following resolutions were passed b
